Community-acquired pneumonia (CAP) has significant morbidity and mortality. The Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines recommend two antimicrobial regimens for hospitalized patients with CAP, one of which includes a macrolide, and one of which does not. Both regimens have antimicrobial properties, but macrolides also possess immunomodulatory properties. Macrolides, however, may also have potential arrhythmia adverse effects. The purpose of this review is to provide an update of studies evaluating outcomes for patients with CAP treated with or without a macrolide-based regimen. Two recent randomized controlled trials conflict with each other regarding the benefit versus noninferiority of including a macrolide for the treatment for CAP. Each have their respective limitations. Most prior observational studies and meta-analyses favor using a regimen with a macrolide. We do not recommend any different treatment strategy than the current IDSA/ATS guidelines for CAP. Further studies need to occur to define the optimal treatment for CAP.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Arnold, Forest W. and Beavin, Leslie A.
"A Review of Macrolide Based Regimens for Community-Acquired Pneumonia,"
The University of Louisville Journal of Respiratory Infections: Vol. 1
, Article 6.
Available at: https://ir.library.louisville.edu/jri/vol1/iss1/6
Community Health and Preventive Medicine Commons, Epidemiology Commons, Health Information Technology Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, International Public Health Commons, Translational Medical Research Commons